Lung Cancer and Native Americans

Understanding the Lung Cancer Burden in Native Communities

“Native American” is commonly used as an umbrella term, but health agencies often report data using the category American Indian and Alaska Native, abbreviated as AI/AN. Even that category includes hundreds of distinct Tribal Nations, communities, languages, traditions, health systems, and local risk environments.

That diversity matters because lung cancer is not distributed evenly. Research has found substantial regional differences in both lung cancer incidence and mortality among AI/AN populations. Historical analyses identified more than a sixfold variation in lung cancer death rates across Indian Health Service regions. Rates were particularly high in areas such as the Northern Plains, Southern Plains, and Alaska, while substantially lower rates appeared in the Southwest.

The American Cancer Society has reported a similarly dramatic regional pattern. Lung cancer incidence among AI/AN people ranged from approximately 16.8 cases per 100,000 people in the Southwest to 109.3 per 100,000 in the Northern Plains. In other words, a single national average can conceal several very different realities.

Evidence:

Why National Averages Can Be Misleading

Imagine averaging the weather in Alaska and Arizona and announcing that everyone should wear a light jacket. Mathematically possible? Yes. Practically useful? Not especially.

Lung cancer statistics work the same way. Differences in commercial cigarette use, local tobacco-control policies, housing conditions, radon exposure, occupational hazards, access to screening, rurality, income, and health care availability can influence regional outcomes. Accurate planning therefore requires regional and Tribal data rather than assumptions based on one nationwide number.

Data quality presents another challenge. American Indian and Alaska Native patients have historically been misclassified in medical and cancer records, which can make disease rates appear lower than they really are. Newer cancer databases improve accuracy by linking records with Indian Health Service information and applying methods intended to reduce racial misclassification.

Evidence:

Commercial Tobacco Is Not Traditional Tobacco

Any responsible discussion of Native Americans and lung cancer must distinguish commercial tobacco from traditional or sacred tobacco. Treating them as interchangeable is medically inaccurate and culturally disrespectful.

Commercial tobacco products are manufactured and marketed for frequent recreational use. Cigarettes contain a toxic mixture of thousands of chemicals, including many known carcinogens. Traditional tobacco, by contrast, may be used by some Indigenous communities in prayer, ceremony, healing, gifting, or cultural practice. Traditions vary widely, and some tribes do not use tobacco ceremonially at all.

Public health programs increasingly use the phrase “commercial tobacco-free” rather than simply “tobacco-free.” This language supports cancer prevention while respecting traditional practices. It also helps avoid the unfortunate public health strategy of insulting the people a program is supposed to servea strategy with a remarkably poor success rate.

On average, AI/AN adults have experienced higher cigarette-smoking prevalence than many other racial and ethnic populations in the United States. They may also face greater exposure to secondhand smoke or fewer comprehensive smoke-free protections in certain areas. These patterns contribute to preventable lung disease, cardiovascular disease, and cancer.

Evidence:

Why Commercial Tobacco Use Remains Complex

Smoking behavior is not simply a matter of personal discipline. Commercial tobacco use can be influenced by stress, poverty, targeted advertising, historical trauma, limited access to cessation treatment, social environments, and the availability of tobacco products. Nicotine dependence is also a medical conditionnot a personality defect wearing a denim jacket.

Effective cessation programs recognize these realities. They combine counseling, medications when appropriate, family and community support, culturally relevant messages, and repeated opportunities to quit. A person may need several attempts before permanently stopping. Each attempt can still provide useful experience and move that person closer to success.

Lung Cancer Risk Factors Beyond Cigarette Smoking

Commercial cigarette smoking remains the leading cause of lung cancer and is associated with roughly 80% of lung cancer deaths in the United States. However, people who have never smoked can also develop the disease. No patient should be dismissed because a clinician, relative, or internet commenter believes lung cancer belongs exclusively to smokers.

Evidence:

Additional lung cancer risk factors include:

• Secondhand exposure to cigarette, cigar, or pipe smoke
• Radon accumulating inside homes or other buildings
• Workplace exposure to asbestos, diesel exhaust, arsenic, silica, or certain metals
• Outdoor air pollution
• A personal history of radiation to the chest
• A family history of lung cancer or inherited susceptibility
• Previous lung disease in some patients

Radon Deserves More Attention

Radon is a naturally occurring radioactive gas produced as uranium, thorium, and radium break down in rock, soil, and groundwater. It has no color, smell, or taste, so a home can have a radon problem without announcing it through an alarming odor or a tiny radioactive doorbell.

Testing is the only reliable way to determine a building’s radon level. Homes in both rural and urban areas may be affected. Tribal housing programs, public health departments, environmental agencies, and community organizations can help expand access to testing and mitigation, particularly where cost and contractor availability are barriers.

Evidence:

Recognizing Possible Lung Cancer Symptoms

Early lung cancer may not cause noticeable symptoms. When symptoms do appear, they can resemble infections, asthma, chronic obstructive pulmonary disease, or other common conditions. That overlap can delay evaluation, especially when patients must travel long distances for imaging or specialist care.

Possible lung cancer symptoms include:

• A cough that does not go away or becomes worse
• Coughing up blood
• Chest pain
• Shortness of breath or wheezing
• Unexplained weight loss
• Persistent fatigue
• Repeated pneumonia or other chest infections
• Swollen lymph nodes around the chest or neck
• Hoarseness or a noticeable change in the voice

Most coughs are not caused by cancer, but a persistent or changing symptom deserves medical attention. The lungs are not famous for sending polite calendar invitations. When something continues to feel wrong, it is reasonable to ask for another evaluation.

Evidence:

Lung Cancer Screening Can Find Disease Earlier

Screening is performed before symptoms appear. The recommended test for people at high risk is low-dose computed tomography, commonly called an LDCT scan. A standard chest X-ray is not considered an adequate replacement for recommended LDCT screening.

Who May Be Eligible?

The U.S. Preventive Services Task Force recommends annual LDCT screening for adults ages 50 through 80 who have at least a 20 pack-year smoking history and either currently smoke or quit within the past 15 years.

The American Cancer Society also recommends yearly LDCT screening for people ages 50 through 80 with at least a 20 pack-year history who currently smoke or formerly smoked. Its current guideline does not use a specific number of years since quitting to exclude former smokers.

A pack-year sounds like something offered by a moving company, but the calculation is straightforward. Smoking one pack per day for 20 years equals 20 pack-years. Smoking two packs per day for 10 years also equals 20 pack-years.

Evidence:

Why Screening Access Remains Unequal

Being eligible for screening does not guarantee receiving it. Some Native patients live hours from a facility offering LDCT scans. Others encounter limited appointment availability, transportation problems, unstable insurance coverage, incomplete smoking histories, or insufficient follow-up after an abnormal scan.

A strong screening program needs more than a scanner. It requires outreach, shared decision-making, smoking-cessation support, transportation, radiology interpretation, patient navigation, follow-up imaging, biopsy services, and access to treatment. Finding a suspicious nodule and then leaving the patient to navigate the next six departments alone is not a complete screening program.

Barriers to Timely Diagnosis and Treatment

American Indian and Alaska Native patients may receive care through Indian Health Service facilities, tribally operated health programs, urban Indian organizations, private health systems, Medicare, Medicaid, Veterans Health Administration facilities, or combinations of these systems. Coordinating referrals and records across multiple organizations can become complicated quickly.

Potential barriers include:

• Long distances to oncology, thoracic surgery, radiation, or imaging services
• Transportation and lodging expenses
• Limited specialty services in rural communities
• Delays in referrals, authorizations, or diagnostic procedures
• Insufficient paid leave or difficulty leaving family responsibilities
• Limited broadband for telehealth appointments
• Language differences or a shortage of trained interpreters
• Mistrust rooted in personal discrimination and historical medical harm
• Poor communication between health systems

These barriers are not evidence that Native patients are “noncompliant.” That label can conceal practical problems. A patient who misses an appointment three hours from home may need a ride, gas money, childcare, lodging, or a referral coordinatornot a lecture.

Evidence:

How Lung Cancer Is Diagnosed

An abnormal screening scan or persistent symptom usually begins a diagnostic process rather than confirming cancer immediately. Doctors may order a diagnostic CT scan, positron emission tomography scan, bronchoscopy, needle biopsy, pulmonary-function testing, blood tests, or additional imaging.

A biopsy is generally needed to identify the cancer type. Lung cancer is divided into two major categories:

• Non-small cell lung cancer: The most common category, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
• Small cell lung cancer: A less common but typically faster-growing form strongly associated with commercial tobacco exposure.

Staging determines how far the cancer has spread. Molecular testing may also look for tumor changes that can be treated with targeted medications. Biomarker testing is especially important for many patients with advanced non-small cell lung cancer.

Treatment Options and the Importance of Coordinated Care

Lung cancer treatment depends on the cancer type, stage, molecular profile, lung function, other medical conditions, and the patient’s priorities. Options may include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, or a combination of treatments.

Early-stage non-small cell lung cancer may sometimes be treated with surgery or focused radiation. Locally advanced disease may require chemotherapy and radiation, sometimes followed by immunotherapy. Advanced cancers may be treated with systemic therapies selected according to tumor biology and the patient’s overall health.

Small cell lung cancer is often treated with chemotherapy and radiation, although the exact plan depends on whether the disease is limited or extensive. Supportive and palliative care can be introduced at any stage to manage pain, breathing difficulty, fatigue, nausea, anxiety, and other symptoms. Palliative care is not the same as giving up; it is specialized symptom support, which is a considerably more useful definition.

Evidence:

Culturally Responsive Cancer Care

Culturally responsive care begins by asking rather than assuming. Some patients may want extended family involved in decisions. Others may prefer privacy. Some may use traditional healing practices alongside medical treatment, seek guidance from elders, or request time for prayer and ceremony. Many will not.

Clinicians should ask patients which people, traditions, spiritual practices, or community resources they want included. Traditional healing and oncology care do not automatically need to compete. The medical team should discuss possible interactions between herbs, supplements, ceremonies involving smoke, fasting practices, and cancer treatments without ridicule or dismissal.

Native patient navigators and community health representatives can help patients understand appointments, arrange transportation, communicate with specialists, prepare questions, and coordinate support. Trust is rarely produced by a brochure. It develops through respectful relationships and consistent follow-through.

Prevention Strategies That Respect Native Communities

Support Commercial Tobacco Cessation

Quitting commercial smoking reduces lung cancer risk, even after years of use. Effective treatment may include counseling, nicotine-replacement products, prescription medications, text-message programs, quitlines, and support from family or community members.

SmokefreeNATIVE, developed through collaboration between the Indian Health Service and the National Cancer Institute, provides culturally aligned text-message support for American Indian and Alaska Native people who want to stop using commercial tobacco. Programs like this acknowledge the distinction between sacred tobacco and manufactured commercial products.

Evidence:

Expand Smoke-Free Environments

Commercial tobacco-free homes, workplaces, vehicles, casinos, and community buildings can reduce secondhand smoke exposure. Tribal governments have sovereign authority to develop policies that fit their communities and cultural practices.

Bring Screening Closer to Patients

Mobile CT programs, transportation assistance, telehealth consultations, community screening events, and direct partnerships between Tribal clinics and cancer centers can reduce travel burdens. Programs should also track whether patients receive follow-up care after abnormal scans.

Improve Local Data

Tribal-specific and regional data can identify communities with unusually high risk. Data-sharing agreements should respect Tribal sovereignty, governance, privacy, and community ownership. Native people should be partners in research design and interpretation, not merely rows in someone else’s spreadsheet.

Include Community Voices

Cancer programs are more likely to succeed when Native survivors, caregivers, elders, clinicians, community health workers, and Tribal leaders help design them. Community engagement should begin before the grant proposal is finishednot five minutes before the group photograph.

A Composite Experience: Navigating Lung Cancer in a Native Community

The following approximately 500-word narrative is a composite illustration. It is not the story of one specific patient and does not represent every Native person or community.

Jordan had been coughing for months, but the cough seemed easy to explain. Winter air was dry, several relatives had caught respiratory infections, and Jordan had smoked commercial cigarettes for years. The nearest clinic was close enough for routine visits, but advanced imaging required a drive to a regional hospital. Missing work for an entire day felt excessive for “just a cough.”

When the cough became painful and Jordan noticed blood in the sputum, a family member insisted on another appointment. The clinician ordered a CT scan. Scheduling it required several telephone calls, confirmation that the referral had arrived, and help from a community health representative who knew which office to contact. Without that assistance, the referral might have spent another week resting peacefully in a fax machine.

The scan showed a suspicious mass. Jordan then needed a biopsy at a cancer center almost three hours away. A sister drove, an aunt watched the children, and the Tribe’s patient-assistance program helped with fuel and lodging. The practical work surrounding the appointment involved nearly as many people as the medical procedure itself.

After the biopsy confirmed non-small cell lung cancer, the oncologist explained the stage, treatment choices, and additional biomarker testing. Jordan understood only parts of the conversation. New words arrived rapidlynodes, margins, mutations, immunotherapywhile fear occupied most of the available mental bandwidth.

At the next visit, a Native patient navigator joined the discussion. She helped Jordan prepare questions, translated medical language into ordinary language, and asked the oncologist to slow down. She also asked Jordan who should receive treatment updates and whether any cultural or spiritual practices needed to be considered.

Jordan wanted close family involved but did not want every relative receiving daily reports. A trusted elder offered prayer, while the oncology pharmacist reviewed herbal products Jordan sometimes used. One supplement could interfere with treatment, so Jordan stopped taking it. The discussion was respectful: no eye-rolling, no assumption that cultural practices were foolish, and no expectation that traditional support should replace medical care.

Treatment included chemotherapy and immunotherapy. Side effects made travel exhausting. Some follow-up appointments could be handled by telehealth from the local clinic, while laboratory testing occurred closer to home. Other visits still required the long drive. The care team grouped appointments whenever possible, reducing the number of separate trips.

Quitting commercial cigarettes was difficult, especially during treatment-related stress. Jordan used nicotine-replacement therapy, counseling, and culturally tailored text messages. There was one relapse. The counselor treated it as information rather than failure, adjusted the plan, and helped Jordan try again.

What improved the experience was not one dramatic breakthrough. It was coordination: a clinician who took the cough seriously, a relative willing to drive, transportation support, a navigator who returned calls, specialists who explained choices, and a community that offered help without taking control away from the patient.

Jordan’s experience illustrates an important truth about lung cancer care. Modern treatments matter enormously, but patients must be able to reach them. Equity is not achieved merely by placing an advanced therapy on a hospital shelf. It requires building a workable path from the patient’s front door to diagnosis, treatment, recovery, and long-term follow-up.

Conclusion

Lung cancer among Native Americans is not one uniform public health problem. Rates differ dramatically by region, and every community has its own strengths, risks, resources, and priorities. Commercial smoking remains a major preventable cause, but radon, secondhand smoke, occupational exposures, delayed diagnosis, and limited access to specialty care also deserve attention.

Progress requires culturally respectful commercial tobacco cessation, expanded LDCT screening, reliable follow-up, accurate data, patient navigation, transportation support, and genuine partnerships with Tribal communities. It also requires listening. Native patients are not statistics waiting to be studied; they are decision-makers whose knowledge and experiences should shape cancer care.

When prevention, early detection, evidence-based treatment, and community leadership move in the same direction, more lung cancers can be found earlier and more patients can receive the care they need. That is not special treatment. It is what a functional health system is supposed to do.